International journal of antimicrobial agents · 2025
Impact of DNA-stored mutations on virological response in virologically suppressed PWH in the switch to modern regimens.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lombardi Francesca, Cacciola Elio Gentilini, Carli Federica, Saladini Francesco, Bassani Francesco, Vicenti Ilaria, Gennari William, Pupo Anita, Duca Leonardo, Christelle Ka'e Aude, Muscatiello Chiara, Pezzati Laura, Khalili Omar El, Shallvari Adarian, Micheli Valeria, Bezenchek Antonia, Cozzi-Lepri Alessandro, Rusconi Stefano, Santoro Maria Mercedes
Аннотация
OBJECTIVE: The clinical relevance of genotypic resistance testing (GRT) performed on viral DNA is still debated. Here, we investigate the role of archived resistance on the virological rebound (VR) after switching treatment.
METHODS: This retrospective study enrolled virologically suppressed people with HIV (PWH) included in the ARCA database with one proviral GRT performed in the 6 months prior to the switch to a modern regimen. Baseline genotypic susceptibility scores (GSS) from HIV-1 DNA GRT (DNA-GSS) and, for a subgroup, from historical plasma GRT (hRNA-GSS) were calculated based on the switch regimen. Survival analysis was used to assess the probability and predictors of VR.
RESULTS: A total of 300 PWH were analysed; 23 % of them showed full or intermediate resistance (DNA-GSS <2). After the therapy switch, the overall probability of experiencing VR was 13.7 %, with PWH with DNA-GSS <2 showing a higher adjusted hazard risk of VR (aHR 2.15, 95 % CI, 1.08-4.27, P = 0.028). Shorter time under suppression preswitch was a negative predictor of VR (per 1-year increase, aHR 0.84 95 % CI, 0.75-0.93, P = 0.001). In the subgroup of PWH with historical plasma GRT (n = 129), hRNA-GSS was not associated with VR, while PWH with an intermediate or full resistance found in both DNA-GSS and hRNA-GSS had the highest probability of experiencing VR.
CONCLUSIONS: Our findings evidence the role of archived resistance in predicting VR after switch therapy in suppressed PWH. Thus, proviral GRT could be a useful tool to optimise strategies for switching treatment, especially if paired with information on previous historical resistance and the duration under suppression.
METHODS: This retrospective study enrolled virologically suppressed people with HIV (PWH) included in the ARCA database with one proviral GRT performed in the 6 months prior to the switch to a modern regimen. Baseline genotypic susceptibility scores (GSS) from HIV-1 DNA GRT (DNA-GSS) and, for a subgroup, from historical plasma GRT (hRNA-GSS) were calculated based on the switch regimen. Survival analysis was used to assess the probability and predictors of VR.
RESULTS: A total of 300 PWH were analysed; 23 % of them showed full or intermediate resistance (DNA-GSS <2). After the therapy switch, the overall probability of experiencing VR was 13.7 %, with PWH with DNA-GSS <2 showing a higher adjusted hazard risk of VR (aHR 2.15, 95 % CI, 1.08-4.27, P = 0.028). Shorter time under suppression preswitch was a negative predictor of VR (per 1-year increase, aHR 0.84 95 % CI, 0.75-0.93, P = 0.001). In the subgroup of PWH with historical plasma GRT (n = 129), hRNA-GSS was not associated with VR, while PWH with an intermediate or full resistance found in both DNA-GSS and hRNA-GSS had the highest probability of experiencing VR.
CONCLUSIONS: Our findings evidence the role of archived resistance in predicting VR after switch therapy in suppressed PWH. Thus, proviral GRT could be a useful tool to optimise strategies for switching treatment, especially if paired with information on previous historical resistance and the duration under suppression.